Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/4683607 |
id |
doaj-95b7bbaf19d2452ba4a2112d50f84d15 |
---|---|
record_format |
Article |
spelling |
doaj-95b7bbaf19d2452ba4a2112d50f84d152020-11-24T22:28:51ZengHindawi LimitedJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/46836074683607Immune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumEileen S. Kim0Jennifer E. Kim1Mira A. Patel2Antonella Mangraviti3Jacob Ruzevick4Michael Lim5Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USAImmune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.http://dx.doi.org/10.1155/2016/4683607 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eileen S. Kim Jennifer E. Kim Mira A. Patel Antonella Mangraviti Jacob Ruzevick Michael Lim |
spellingShingle |
Eileen S. Kim Jennifer E. Kim Mira A. Patel Antonella Mangraviti Jacob Ruzevick Michael Lim Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Journal of Immunology Research |
author_facet |
Eileen S. Kim Jennifer E. Kim Mira A. Patel Antonella Mangraviti Jacob Ruzevick Michael Lim |
author_sort |
Eileen S. Kim |
title |
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
title_short |
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
title_full |
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
title_fullStr |
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
title_full_unstemmed |
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
title_sort |
immune checkpoint modulators: an emerging antiglioma armamentarium |
publisher |
Hindawi Limited |
series |
Journal of Immunology Research |
issn |
2314-8861 2314-7156 |
publishDate |
2016-01-01 |
description |
Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation. |
url |
http://dx.doi.org/10.1155/2016/4683607 |
work_keys_str_mv |
AT eileenskim immunecheckpointmodulatorsanemergingantigliomaarmamentarium AT jenniferekim immunecheckpointmodulatorsanemergingantigliomaarmamentarium AT miraapatel immunecheckpointmodulatorsanemergingantigliomaarmamentarium AT antonellamangraviti immunecheckpointmodulatorsanemergingantigliomaarmamentarium AT jacobruzevick immunecheckpointmodulatorsanemergingantigliomaarmamentarium AT michaellim immunecheckpointmodulatorsanemergingantigliomaarmamentarium |
_version_ |
1725746016435568640 |